Management and Prevention of Bone Complications Supportive Care

Xgeva Reduces Bone Complications From Prostate Cancer (02-25-2011)

Among men with bone metastases from prostate cancer, Xgeva™ (denosumab) was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from this Phase III clinical trial were published in The... Continue Reading

Xgeva Delays Bone Complications in Women with Metastatic Breast Cancer (12-21-2010)

In a study of women with bone metastases from breast cancer, Xgeva™ (denosumab) delayed bone complications for five months longer than Zometa® (zoledronic acid). These updated results from a Phase III clinical trial were presented at the 2010 San Antonio... Continue Reading

Xgeva Approved for Patients with Bone Metastases (11-30-2010)

Xgeva™ (denosumab) has been approved by the US Food and Drug Administration (FDA) for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood-related) cancers. It is not approved for patients with... Continue Reading

Denosumab Delays Bone Complications in Women with Metastatic Breast Cancer (11-23-2010)

Among women with bone metastases from breast cancer, denosumab may be more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. The results of this Phase III clinical trial were published in the Journal... Continue Reading

Denosumab More Effective Than Zometa at Delaying Bone Complications (10-15-2010)

Among patients with multiple myeloma or bone metastases from breast cancer, prostate cancer, or other solid tumors, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from... Continue Reading

Bisphosphonates May Provide Breast Cancer Benefits (12-11-2009)

Studies presented at the 2009 San Antonio Breast Cancer Symposium suggest that the class of bone drugs known as bisphosphonates may reduce the risk of breast cancer and may help to maintain bone density in breast cancer patients treated with aromatase... Continue Reading

Denosumab Reduces Bone Complications in Breast Cancer Patients with Bone Metastases (12-10-2009)

Among women with bone metastases from breast cancer, the investigational drug denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. The results of this Phase III clinical trial were... Continue Reading

Denosumab Provides Bone Benefits in Advanced Cancer (09-21-2009)

Among patients with bone metastases from cancers other than breast or prostate cancer, denosumab is at least as effective as Zometa® (zoledronic acid) at reducing the risk of bone complications. These results were presented at a major European cancer... Continue Reading

Denosumab Reduces Fractures in Postmenopausal Osteoporosis (08-12-2009)

Denosumab increases bone mineral density (BMD) and reduces the risk of vertebral fractures in women with postmenopausal osteoporosis, according to the results of a study published in the New England Journal of Medicine.[i] Denosumab is an investigational... Continue Reading

Denosumab Reduces Fractures in Non-metastatic Prostate Cancer (08-11-2009)

Men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer experienced a 62% reduction in risk of vertebral fractures when treated with denosumab compared to men treated with placebo, according to the results of a study published... Continue Reading

Next Page »